Velakast (Sofosbuvir + Velpatasvir) Tablets
Velakast (Sofosbuvir 400 mg + Velpatasvir 100 mg) is a fixed-dose combination generic of Epclusa, manufactured by Aprazer.
Official License: Produced under a license from Gilead Sciences, ensuring it meets the same quality standards as the original US brand. It is a "Pan-Genotypic" Direct-Acting Antiviral (DAA), meaning one pill cures all major strains of Hepatitis C.
Mechanism of Action:
By combining two potent inhibitors (NS5B + NS5A) in a single tablet, Velakast stops the virus from replicating and assembling new particles. It offers a simple, one-pill-a-day regimen.
✅ Efficacy: Cure rates exceeding 98-99% across all genotypes after a 12-week course.
Indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults:
- 🦠 Genotypes 1-6: Universal treatment (no need for genotype testing in resource-limited settings).
- 🏥 Liver Condition: Effective for patients without cirrhosis or with compensated cirrhosis.
- ➕ Combinations: Used with Ribavirin for decompensated cirrhosis.
Packaging: Bottle of 28 tablets (4-week supply).
⚠️ ADMINISTRATION PROTOCOL:
- 💊 Dose: Take ONE tablet once daily. Swallow whole (do not chew or crush due to bitter taste).
- ⏰ Consistency: Take at the same time every day. Never miss a dose.
- 🍽️ Food: Can be taken with or without food.
- 📅 Duration: The standard treatment duration is 12 weeks (3 bottles) for most patients.
- Pregnancy and breastfeeding.
- Co-administration with Amiodarone (severe heart risk).
- Acid Reducers (PPIs): Drugs like Omeprazole reduce Velpatasvir absorption. Take Velakast 4 hours before antacids.
- Use of St. John’s Wort or Rifampin.
Side effects are generally mild and transient:
- 🤕 Common: Headache and fatigue are the most reported.
- 🤢 Gastrointestinal: Mild nausea.
- Most patients maintain their normal daily routine during treatment.
What Customers Say
No reviews yet
Your review can be the first!